Drugs / CSX-1004
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06005402 | Aug 2023 → May 2024 | acute opioid poisoning, opiate dependence | Cessation Therapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CSX-1004 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06005402 ↗ |
| Modality | Monoclonal antibody | “monoclonal antibody specific for fentanyl and structurally related fentanyl analogs” NCT06005402 ↗ |
| Route | Intravenous | “administered by IV infusion” NCT06005402 ↗ |